Eupraxia Pharmaceuticals (EPRX) Prepaid Assets (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Prepaid Assets of $2.6 million for Q1 2026, up 182.83% year-over-year from $913283.0 in Q1 2025, and down 33.1% quarter-over-quarter from $3.9 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Prepaid Assets (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Prepaid Assets for 5 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 182.83% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 182.83% YoY), while the FY2025 annual figure was $3.9 million, up 248.92% from the prior year.
- Prepaid Assets retreated to $2.6 million in Q1 2026 per EPRX's latest filing, from $3.9 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $3.9 million in Q4 2025 and bottomed at $140928.0 in Q1 2024.
- Historically, Prepaid Assets has averaged $1.6 million across 5 years, with a median of $1.1 million in 2024.
- Annual changes were most pronounced in 2023 — Prepaid Assets increased 14.75% — and 2025, when it soared 548.05%.
- Eupraxia Pharmaceuticals' Prepaid Assets stood at $235903.0 in 2022, then rose by 14.75% to $270710.0 in 2023, then jumped by 308.74% to $1.1 million in 2024, then surged by 248.92% to $3.9 million in 2025, then sank by 33.1% to $2.6 million in 2026.
- Business Quant data shows EPRX's Prepaid Assets at $2.6 million in Q1 2026, $3.9 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.58 Mn |
| Dec 31, 2025 | 3.86 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 2.93 Mn |
| Mar 31, 2025 | 913,283.00 |
| Dec 31, 2024 | 1.11 Mn |
| Mar 31, 2024 | 140,928.00 |
| Dec 31, 2023 | 270,710.00 |
| Dec 31, 2022 | 235,903.00 |